Stock Financial Ratios, Dividends, Split History

GPS / Gap, Inc. (The) financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price33.75
Volume6,172,500.00
Market Cap ($M)11,286.35
Enterprise Value ($M)10,752.35
Book Value ($M)3,197.00
Book Value / Share8.25
Price / Book3.59
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 389,000,000
Weighted Average Number Diluted Shares Outstanding Adjustment 3,000,000
Common Shares Outstanding 389,318,839
Weighted Average Number Of Diluted Shares Outstanding 396,000,000
Weighted Average Number Of Shares Outstanding Basic 393,000,000
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.19
Return on Assets (ROA)0.11
Return on Equity (ROE)0.29
Balance Sheet (mrq) ($M)
Assets7,585.00
Liabilities4,388.00
Quick Ration/a
Current Ratio2.03
Income Statement (mra) ($M)
Incomefrom Revenue Sharingfrom Credit Card Programs412,000,000.00
Sales Revenue Net15,855,000,000.00
Operating Income1,479.00
Net Income848.00
Earnings Per Share Basic2.16
Earnings Per Share Diluted2.14
Cash Flow Statement (mra) ($M)
Cash From Operations1,380.00
Cash from Investing-668.00
Cash from Financing-668.00
Identifiers and Descriptors
CUSIP364760108
Central Index Key (CIK)39911
Related CUSIPS
364760908 364760958

Split History

Stock splits are used by Gap, Inc. (The) to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

13h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

13h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

Gap (GPS) Feels the Pinch of Soft Q1: Is It Time to Offload?

1h zacks
The Gap Inc. (GPS - Free Report) has been putting a dismal show lately owing to bleak earnings performance in the last reported quarter. It missed earnings estimates in first-quarter fiscal 2018, after four straight quarters of beat. Further, the company is witnessing softness across its namesake brand, which has been a key impediment for quite some time. Though shares of Gap gained 8.7% in the past three months, it lagged the industry’s 15. (16-0)

On-Call Work Schedules Make It Hard to Have a LIfe - Bloomberg

2018-06-18 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (2-0)

20 Long-Term Value Stocks With Hulking Upside

2018-06-14 investorplace
In the value stocks versus growth stocks tug-of-war, growth stocks have been the unequivocal winner for the past several years. But that may change soon. (518-0)

Retail Sales Are On Fire – 5 Top Stocks To Buy Now

2018-06-14 247wallst
For the last five years we were told over and over that Amazon.com (NASDAQ: AMZN) would ultimately change retail as we know it, and the end for brick-and-mortar chains was right around that corner. Guess what? While the Amazon model surely changed the landscape of retail, mostly for the better, and certainly for the future, the predictions of retail doom were overstated. (101-1)

Business News Roundup, June 14

2018-06-13 sfgate
The Federal Reserve raised interest rates by a quarter of a percentage point Wednesday and signaled it will raise rates two more times this year, as Fed Chairman Jerome Powell proclaimed the U.S. economy to be in “great shape” and that “most people who want to find jobs are finding them.” (2-0)

CUSIP: 364760108